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Background: The tyrosine kinase receptor insulin-like growth factor 1 receptor (IGF-IR) contributes to the initiation
and progression of many types of malignancies. We previously showed that IGF-2, which binds IGF-IR, is an extrinsic
factor that supports the ex vivo expansion of hematopoietic stem cells (HSCs). We also demonstrated that IGF-IR is
not required for HSC activity in vivo.
Methods and results: Here we investigated the role of IGF-IR in chronic myeloid leukemia (CML) using the retroviral
BCR/ABL transplantation mouse model. Existing antibodies against IGF-IR are not suitable for flow cytometry; therefore,
we generated a fusion of the human IgG Fc fragment with mutant IGF-2 that can bind to IGF-IR. We used this fusion
protein to evaluate mouse primary hematopoietic populations. Through transplantation assays with IGF-IR+ and IGF-IR−
cells, we demonstrated that IGF-IR is expressed on all mouse HSCs. The expression of IGF-IR is much higher on CML
cells than on acute lymphoblastic leukemia (ALL) cells. The depletion of IGF-IR expression in BCR/ABL+ cells led to the
development of ALL (mostly T cell ALL) but not CML. Lack of IGF-IR resulted in decreased self-renewal of the BCR/ABL+
CML cells in the serial replating assay.
Conclusion: IGF-IR regulates the cell fate determination of BCR/ABL+ leukemia cells and supports the self-renewal of
CML cells.
Keywords: Leukemia, Chronic myeloid leukemia, Acute lymphoblastic leukemia, Hematopoietic stem cells, Tyrosine
kinase receptor, BCR/ABL, IGF-IRIntroduction
Chronic myeloid leukemia (CML) is a hematopoietic malig-
nancy that results from the t(9;22)(q34;q11) Philadelphia
(Ph) chromosome translocation, which produces the BCR/
ABL fusion oncogene [1-3]. Tyrosine kinase inhibitors
(TKIs) effectively treat symptoms of CML patients, but
the disease is not curable in most cases. Both BCR/ABL
dependent and independent mechanisms contribute to
TKI resistance. The BCR/ABL dependent resistance may
result from duplication, overamplification, or mutation of
the gene encoding BCR/ABL [4-7]. BCR/ABL independent
resistance mechanisms result from drug efflux or influx or
activation of alternative signaling pathways [8,9]. CML-
initiating cells (CML-ICs) in patients have been shown to
be insensitive to TKIs [10]. Novel targets in CML-ICs* Correspondence: alec.zhang@utsouthwestern.edu
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egies to eliminate CML.
Insulin-like growth factor 1 receptor (IGF-IR) is a re-
ceptor tyrosine kinase. IGF-IR is a homodimer of α and
β subunits that recognizes ligands IGF-1 and IGF-2 [11].
IGF-IR-mediated signaling is important for normal de-
velopment and contributes to the initiation and progres-
sion of many types of solid malignancies [11-14]. IGF-IR
also contributes to development of hematopoietic malig-
nancies including acute myeloid leukemia (AML), T cell
acute lymphoblastic leukemia (T-ALL), multiple myeloma,
and CML. Autocrine IGF signaling, mediated through
IGF-IR, supports the growth and survival of AML cells via
the phosphoinositide 3-kinase/Akt pathway [15]. IGF-IR is
also critical for the transformation of MLL-AF9 AML but
is not required for AML propagation [16]. IGF-IR expres-
sion is essential for maintenance of T-ALL stem cells and
is supported by Notch signaling [17,18]. Inhibition of IGF-
IR signaling has a significant antitumor effect on multiple
myeloma in a xenograft model [19]. BCR/ABL upregulates
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progression to the CML blast crisis phase [20].
We previously reported that IGF signaling supports
hematopoietic stem cell (HSC) expansion [21]. However,
IGF-IR is dispensable for HSC activity in mice [22]. Here
we sought to test whether a signaling that is dispensable
to normal HSCs is important to the activity of malignant
CML cells. We found that IGF-IR is highly expressed on
HSCs, and levels of IGF-IR were much higher on CML
cells than on ALL cells. Although IGF-IR is dispensable
for activity of normal HSCs, it is critical to BCR/ABL
leukemia fate determination and self-renewal of CML
cells. Loss of IGF-IR in Ph+ cells resulted in develop-
ment of ALL.
Results
IGF-IR is expressed on the surface of HSCs
We previously showed that IGF-2 stimulates ex vivo ex-
pansion of HSCs [21]. There are three known receptors
for IGF-2: IGF type 1 receptor (IGF-IR), IGF type 2
receptor (IGF-IIR), and insulin receptor. Using a fusion
of IGF-2 and IgG Fc as an affinity reagent, we previously
showed that all repopulating HSCs bound IGFs [21]. Be-
cause existing antibodies against IGF-IR are not suitable
for flow cytometry, we were unable to determine whether
IGF-IR was expressed on HSCs. Thus we generated a fu-
sion protein of IgG Fc with a mutant IGF-2 that can bind
only to IGF-IR but not IGF-IIR (Figure 1A). As described
previously [23], Ala and Leu replacements of Arg54 and
Arg55, respectively, led to an IGF2 (Arg-IGF2) incapable
of binding to IGF-IIR. We used FACS to sort cells based
on their abilities to bind to this mutant IGF2 (Figure 1B).
The lysates of these sorted cells were analyzed by western
blot with antibodies against IGF-IR, confirming that Arg-
IGF2 specifically binds to IGF-IR (Figure 1C). About 30 ±
6% or 18 ± 5% of total fetal liver or bone marrow cells in
mice were IGF-IR+ respectively (Figure 1B). By using
sorted IGF-IR+ and IGF-IR− cells in comparative long-
term bone marrow repopulation assays, we demonstrated
that all mouse fetal liver and adult bone marrow HSCs ex-
press IGF-IR (Figure 1D). Moreover, we used flow cytome-
try to show that, all Lin−Sca-1+Kit+ cells are IGF-IR+
(Figure 1E). Although approximately 50% of Lin−Sca-1+
cells are IGF-IR+ (not shown), all of the repopulating ac-
tivity of Lin−Sca-1+ cells resided in the fetal liver and bone
marrow Lin−Sca-1+IGF-hFc+ fraction (Figure 1F). That
mouse HSCs express IGF-IR suggests a role of IGF signal-
ing in physiology and pathogenesis of HSCs.
IGF-IR regulates BCR/ABL leukemia fates
The fact that IGF-IR is expressed on HSCs but does not
play an essential role in regulation of HSC repopulation
in vivo led us to investigate the role of IGF-IR-mediated
signaling in hematopoietic malignancies. IGF-IR supportshematopoietic malignancies including AML, T-ALL, and
multiple myeloma [15-19]. The presence of the BCR/ABL
fusion is also correlated with elevated IGF-1 expression in
human CML samples. Autocrine IGF signaling supports
progression of the CML blast crisis phase, and, conversely,
inhibition of IGF-1R reduces viability and proliferation of
BCR-ABL+ cells [20]. We therefore used a retroviral BCR-
ABL transplantation mouse model [24-26] to further study
the role of IGF-IR in regulation of BCR/ABL leukemia
development. Wild-type (WT) or IGF-IR-null donor fetal
liver Lin− cells infected by retroviral BCR-ABL-IRES-GFP
were used to induce leukemia. The lack of IGF-IR did not
change the level of expression of the mRNA encoding
BCR/ABL (Figure 2A). We next investigated whether IGF-
IR was required for the induction of leukemia by BCR/
ABL. Mice transplanted with BCR/ABL-transduced WT
and IGF-IR cells had similar GFP+ cells at 3 months
(Figure 2B), suggesting IGF-IR is not essential for BCR/
ABL leukemia propagation. Consistently, IGF-IR defi-
ciency did not cause a significant alteration in the survival
of leukemic mice (Figure 2C). However, there was a much
less severe infiltration of IGF-IR-null myeloid leukemia
cells into the lung, liver, and spleen compared to levels
of WT cells (Figure 2D-E), suggesting that IGF-IR does
impact leukemia development.
Samples from mice transplanted with IGF-IR-null BCR/
ABL cells and those transplanted with WT BCR/ABL cells
were analyzed by flow cytometry and cytospin staining for
cells characteristic of CML and ALL (Figure 3A-B). Over
60% of WT BCR/ABL-infected cells developed into CML,
and the rest developed into ALL. In contrast, all IGF-IR-
null BCR/ABL cells resulted in ALL, with T-ALL observed
in most cases (Figure 3C-D, 26 out of 28 cases were
T-ALL). While the mice with the null leukemia might
show a delayed trend of death, the difference in types
of leukemia did not significantly alter the survival of
mice infected with WT and IGF-IR-null BCR/ABL
cells (Figure 3D).
In addition to infecting fetal liver Lin− cells, we also
followed the published protocols [25,26] to infect 5-FU
treated bone marrow cells with BCR/ABL-IRES-GFP
retrovirus. Concordant with reported results, all the
recipient mice transplanted with BCR/ABL virus infected
WT cells developed CML-like disease. Three recipient
mice survived 20, 29, and 31 days respectively. In con-
trast, all the recipient mice transplanted with IGF-IR-
null BCR/ABL cells developed ALL and survived 29, 35,
and 46 days respectively. These results confirmed that
the deficiency of IGF-IR results in alteration of fates of
BCR/ABL induced leukemia.
Deficiency in IGF-IR decreases self-renewal of CML cells
We next assessed whether IGF-IR regulates self-renewal
of BCR/ABL leukemia cells. IGF-IR deficiency led to
Figure 1 IGF-2 receptor expression in fetal liver cells. (A) Production and secretion of IGF2-hFc in transfected 293T cells. The upper panel
shows a schematic of the plasmid expressing the human prepro-IGF-2 protein fused to a human IgG1 Fc fragment. The bottom panels show
western Blots of conditioned medium collected 48 hours after transfection from 293T cells transfected with either control or Arg-IGF2-hFc vectors;
blots were probed with antibodies against human IGF-2 (left) or human IgG1 (right). (B) Mouse fetal liver cells (FL) and adult bone marrow cells
(BM) contain IGF-IR+ cells that bind to Arg-IGF-2-hFc as determined by flow cytometry. (C) Western blot of total fetal liver cells sorted based on
binding of Arg-IGF2-hFc. Antibody against IGF-IR (Cell Signaling) was used to detect the expression of IGF-IR in flow cytometry-sorted Arg-IGF2-
hFc+ and Arg-IGF2-hFc− fetal liver cells. These results confirmed the specificity of Arg-IGF2-hFc binding to IGF-IR+ cells. Blotting with anti-beta-
tubulin (Sigma) served as the loading control. (D) All repopulating HSCs in the total population of bone marrow (BM) or fetal liver cells (FL) bind
Arg-IGF2-hFc. One thousand CD45.2 bone marrow or fetal liver Arg-IGF2-hFc+ cells and 1,000 Arg-IGF2-hFc− cells were transplanted together with
2 × 105 CD45.1 competitor cells into lethally irradiated CD45.1 mice (n = 5). Peripheral blood cells were analyzed for the presence of CD45.2+ cells
at 6 months after transplant. (E) All the mouse bone marrow Lin− Sca1+ Kit+ cells are IGF-IR+ cells as determined by flow cytometry. Bone marrow
Lin− cells were gated. (F) All repopulating HSCs in the Lin−Sca-1+Kit+ cells bind Arg-IGF2-hFc. Fifty CD45.2 bone marrow or fetal liver Lin−Sca-1+
Arg-IGF2-hFc+ and 100 Lin−Sca-1+IGF2-hFc− cells were transplanted together with 2 × 105 CD45.1 competitor cells into lethally irradiated CD45.1
mice (n = 4-5). Peripheral blood cells were analyzed for the presence of CD45.2+ cells at 6 months after transplant.
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bone marrow (Figure 4A-B). Colony formation assays
showed that WT and IGF-IR-null BCR/ABL cells had
similar colony forming abilities in primary plating; how-
ever, IGF-IR-null cells had decreased colony forming
capacity upon replating (Figure 4C). These results suggestthat IGF-IR supports the self-renewal of CML cells.
IGF-IR was expressed at significantly higher levels by
BCR/ABL+ CML cells than by T-ALL or B-ALL cells
(Figure 4D-E). Together, our results suggest that the
lack of IGF-IR on CML cells shifts BCR/ABL leukemia
cell fate from CML to ALL.
Figure 2 Lack of IGF-IR alters leukemia development. (A) Expression of mRNA encoding BCR/ABL in GFP+ WT and IGF-IR-null leukemia cells as
determined by real-time RT-PCR. (B) Representative flow cytometry plots showing that WT and IGF-IR-null BCR/ABL transplanted mice have
comparable GFP+ cells at 3 months after transplantation. (C) Survival curve of mice receiving BCR/ABL-infected WT or IGF-IR-null hematopoietic
progenitors (n = 15). (D) Comparison of the sizes of lungs, livers, and spleens of representative mice transplanted with WT BCR/ABL cells and
IGF-IR-null BCR/ABL cells at 3 months after transplantation. (E) Histological analysis of leukemia infiltration in the internal organs of WT and IGF-IR-null
BCR/ABL cells transplanted mice at 3 months (hematoxylin/eosin staining).
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Previously, we showed that IGF-2 stimulates the ex vivo
expansion of HSCs [21]. IGF-IR is not required for
in vivo repopulation of HSCs, however [22]. Here, we
demonstrated that IGF-IR is highly expressed on HSCs
and CML cells but is only expressed at low levels on
ALL cells. Although IGF-IR is dispensable for normal
HSC maintenance, it is critical to BCR/ABL leukemia
fate determination. Loss of IGF-IR in Ph+ leukemia
resulted in development of ALL. That IGF-IR supports
CML cell self-renewal is concordant with the reported
function of IGF-1R in self-renewal of embryonic stem
cells [27] and in ex vivo expansion of HSCs [21]. Like
other signaling pathways, including Wnt/β-catenin and
Hedgehog [28], the IGF-IR signaling system appears to
be dispensable in normal HSCs but activated in leukemiacells. Such signaling pathways contribute specifically to
cancer initiation or progression.
An important question is whether IGF-IR plays differ-
ent roles in different types of cells. Our and others’ stud-
ies clearly indicated that IGF-IR has distinct functions in
different contexts. It is well documented that IGF-IR is
important in a variety of functions in different cancer
types including proliferation, adhesion, migration, sur-
vival, and metastases [12]. While it is not required for
in vivo HSC repopulation, IGF-IR is required for various
leukemia development. As shown here, IGF-IR is neces-
sary for fate determination and self-renewal of CML
cells and blocking IGF-IR signaling inhibits CML devel-
opment but leads to Ph+ ALL. Consistently, IGF-IR
transforms MLL-AF9 AML progenitors but does not to
stimulate leukemia propagation, and blocking IGF-IR
Figure 3 IGF-IR deficiency alters BCR/ABL leukemia fates. (A) Representative flow cytometry plots showing CML, T-ALL, and B-ALL cells in mice
transplanted with WT or IGF-IR-null BCR/ABL cells. (B) Cytospin staining of CML and ALL in mice transplanted with WT or IGF-IR-null BCR/ABL cells.
(C) Percentages of different types of leukemia developed by mice transplanted with BCR/ABL-infected WT or IGF-IR-null hematopoietic progenitors.
(D) Survival curves of mice receiving BCR/ABL-infected WT or IGF-IR-null hematopoietic progenitors that developed different types of leukemia (n = 15).
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different roles in different types of T-ALL. While high
levels of IGF-IR support the activity of T-LBL stem
cells [17], it is clear from our study that BCR/ABL
driven T-ALL does not express a significant level of
IGF-IR and IGF-IR is not required for Ph+ T-ALL
development.
This study raises provocative questions regarding
extrinsic signaling for leukemia stem cells. Is IGF-IR sig-
naling in CML cells independent of BCR/ABL-inducedsignaling? How does IGF signaling, together with other
extrinsic and intrinsic pathways (IL-6, Wnt, Hedgehog,
BMPs, selectin, TGF-β, Alox5, CD25, among others)
[9,28-33], regulate the fates of CML cells including self-
renewal, differentiation, apoptosis, and migration? Given
extensive aberrant signaling in CML cells, we expect that
the combined use of TKIs and inhibition of a limited
number of key extrinsic pathways, including IGF-IR sig-
naling, will lead to the development of novel strategies
for treating CML.
Figure 4 Lack of IGF-IR decreases self-renewal of CML cells. (A-B) LSK percentages dramatically decreased in leukemia bone marrow from
mice transplanted with IGF-IR-null compared to WT BCR/ABL cells as shown in (A) representative flow cytometry plots and (B) as summarized in
the bar graph. (C) IGF-IR-null leukemia cells have dramatically decreased CFU forming ability in second replating (n = 3). (D-E) Expression of IGF-IR
in WT and IGF-IR-null BCR/ABL leukemia cells as determined by (D) real-time RT-PCR and (E) western blotting.
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We developed a novel method to mark IGF-IR on the
surface of cells. Using this flow cytometry-based
method and reconstitution analyses, we found that
IGF-IR is expressed on all mouse HSCs. The expression
of IGF-IR was dramatically higher on CML cells than
on ALL cells. The knockout of IGF-IR in BCR/ABL+
cells led to the development of ALL (mostly T-ALL)
but not CML. Lack of IGF-IR resulted in decreased
self-renewal of the BCR/ABL+ CML cells. Therefore,
IGF-IR directs BCR/ABL+ leukemia cells toward the
myeloid fate. Because IGF-IR is dispensable for the
activity of HSCs but regulates BCR/ABL leukemia cell
fates and supports self-renewal of CML cells, targeting
IGF-IR may be an ideal anti-leukemia strategy. Inhib-
ition of the IGF-IR axis may contribute to the develop-
ment of future combination therapies that selectively
target multiple key signaling pathways unique to CML
cells.Methods
Animals
C57 BL/6 CD45.2 and CD45.1 mice were purchased from
Jackson Lab or National Cancer Institute. IGF-IR+/- mice
as previously described [34] were in a pure C57BL/6 back-
ground. Mice were maintained at the University of Texas
Southwestern Medical Center animal facility. All animal
experiments were performed with the approval of UT
Southwestern Committee on Animal Care.
Expression of IGF-2-hFc
Originally IGF2-hFc was constructed by fusing IGF-2 and
human IgG1 Fc under the control of CMV promoter [21].
The QuikChange Mutagenesis kit (Stratagene) was used
to substitute Arg54-Arg55 with Ala-Leu to produce Arg-
IGF2-hFc. The plasmid was transfected into 293T cells
using Lipofectamine 2000 (Invitrogen). Conditioned
medium was collected 48 hours after transfection. The
conditioned medium with about 1 μg/ml of Arg-IGF-2-
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subsequent staining of fetal liver or bone marrow cells.
Flow cytometry, immunohistochemistry, and cytospin
Flow cytometry, immunohistochemistry, and cytospin
were performed as we described previously [35,36].
Lin− Sca-1+Kit+ cells were detected or sorted as de-
scribed [37-39]. Ala-IGF2-hFc+ and Ala-IGF2-hFc− cells
were stained and sorted using a protocol similar to that
described previously [21]. Briefly, 107 cells were resus-
pended in 1 ml of conditioned medium (with ~1 μg/ml
Arg-IGF2-hFc as determined by western blotting) at
4 oC for 30 minutes followed by staining with anti-
human IgG1 Fc-PE (Jackson ImmunoResearch). The con-
ditioned medium from mock transfected cells was used as
a control. When necessary, the co-staining of biotinylated
Lin+ antibody cocktail followed by streptavidin-APC and
anti-Sca-1-FITC was performed before sorting Lin−Sca-
1+IGF2-hFc+ and Lin−Sca-1+IGF2-hFc− cells in a FAC-
SAria sorter.
For reconstitution analyses, peripheral blood cells were
collected by retro-orbital bleeding. Red blood cells were
lysed and stained with anti-CD45.2-FITC, anti-CD45.1-
PE, anti-Thy1.2-PE, anti-B220-PE, anti-Mac1-PE, anti-
Gr1-PE, or anti-Ter119-PE monoclonal antibodies (BD
Pharmingen) as we described [39,40]. FACS analyses
were performed on a FACSCalibur® instrument.
For flow cytometry analysis of leukemia cells, peripheral
blood or bone marrow cells were stained with anti-
Lineage-Biotin (followed by streptavidin-APC), anti-
Mac1-APC, anti-Gr1-PE, anti-CD3-APC, anti-B220-PE,
or anti-Kit-PE monoclonal antibodies (BD Pharmingen).
Cell cycle status was determined by propidium iodide
staining. For analysis of apoptosis, cells were stained with
PE-conjugated anti-annexin V and 7-AAD (BD Pharmin-
gen) according to the manufacturer’s instructions.
Competitive reconstitution analysis
Indicated numbers of CD45.2 donor cells were mixed
with 1 × 105 freshly isolated CD45.1 competitor bone
marrow cells, which were then injected intravenously via
the retro-orbital route into CD45.1 mice previously irra-
diated with a total dose of 10 Gy. To measure reconsti-
tution of transplanted mice, peripheral blood was
collected by retro-orbital bleeding at the indicated times
post-transplant and the presence of CD45.1+ and
CD45.2+ cells in lymphoid and myeloid compartments
were measured as we described [39].
CML mouse model
The retrovirus transplantation CML mouse model was
prepared essentially as described [25,26]. Bone marrow
cells from 5-FU treated C57BL/6 mice or C57BL/6 fetal
liver Lin− cells were infected with retrovirus carryingMSCV-BCR/ABL-IRES-GFP. The transduced cells (5 ×
105) were transplanted intravenously into lethally irradi-
ated (10 Gy) C57BL/6 recipients.
Colony forming unit (CFU) assays
Cells from leukemia mice were plated in methylcellulose
(M3534, Stem Cell Technologies) for CFU-GM assays
according to the manufacturer’s protocols and our previ-
ously published protocol [35,37,39]. After 7 days, 2000
cells from three dishes were used for secondary replating.
Western blotting
Cell lysates (100 μg samples) were separated by electro-
phoresis on a 4-12% SDS-polyacrylamide gel, and the pro-
teins were electroblotted onto a nitrocellulose membrane.
The membrane was probed with primary antibody for 1
hour at room temperature and then incubated with horse-
radish peroxidase-conjugated secondary antibody, which
was detected with the chemiluminescence SuperSignal kit
(Pierce).
Quantitative RT-PCR
Total RNA was isolated from FACS-collected cells.
First-strand cDNA was synthesized using SuperScript II
RT (Invitrogen). Samples were analyzed in triplicate 25-
μl reactions (300 nM each primer, 12.5 μl of Master
mix) as adapted from the standard protocol provided in
SYBR Green PCR Master Mix and RT-PCR Protocols
provided by Applied Biosystems. Primers were pur-
chased from Qiagen or Sigma. The default PCR protocol
was used on an Applied Biosystems Prism 7000 Se-
quence Detection System. The mRNA level in each
population was normalized to the level of β-actin RNA
transcripts present in the same sample as described
previously [41].
Statistical analyses
Data are expressed as means ± SEM. Data were analyzed
by Student’s t test and were considered statistically sig-
nificant if p < 0.05. The survival rates of the two groups
were analyzed using a log-rank test.
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